{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T18:21:05Z","timestamp":1747160465047,"version":"3.40.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,29]],"date-time":"2024-01-29T00:00:00Z","timestamp":1706486400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.esmogo.2024.100046","type":"journal-article","created":{"date-parts":[[2024,3,9]],"date-time":"2024-03-09T01:02:48Z","timestamp":1709946168000},"page":"100046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world outcomes of trifluridine\/tipiracil for heavily pretreated patients with advanced gastric cancer"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0464-8923","authenticated-orcid":false,"given":"K.","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ooki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Kamiimabeppu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-5699","authenticated-orcid":false,"given":"K.","family":"Shimozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Osumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fukuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1004-8425","authenticated-orcid":false,"given":"M.","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Chin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Shinozaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2492-6014","authenticated-orcid":false,"given":"D.","family":"Takahari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2024.100046_bib1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100046_bib2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1023\/A:1008243606668","article-title":"Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer","volume":"8","author":"Glimelius","year":"1997","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100046_bib3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/annonc\/mdu472","article-title":"Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer","volume":"26","author":"Yamada","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100046_bib4","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100046_bib5","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1007\/s10120-021-01173-w","article-title":"Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab","volume":"24","author":"Boku","year":"2021","journal-title":"Gastric Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100046_bib6","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1093\/oncolo\/oyab069","article-title":"Clinical progress in inoperable or recurrent advanced gastric cancer treatment from 1004 single institute experiences between 2007 and 2018","volume":"27","author":"Nakayama","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.esmogo.2024.100046_bib7","first-page":"249","article-title":"An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA","volume":"13","author":"Emura","year":"2004","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.esmogo.2024.100046_bib8","first-page":"277","article-title":"Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells","volume":"17","author":"Murakami","year":"2000","journal-title":"Int J Oncol"},{"key":"10.1016\/j.esmogo.2024.100046_bib9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.3892\/or.2014.3487","article-title":"Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models","volume":"32","author":"Tanaka","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.esmogo.2024.100046_bib10","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0006-2952(00)00253-7","article-title":"Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2\u02b9-deoxyribonucleosides","volume":"59","author":"Fukushima","year":"2000","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100046_bib11","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","article-title":"Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"19","author":"Shitara","year":"2018","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100046_bib12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"10294","key":"10.1016\/j.esmogo.2024.100046_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10418","key":"10.1016\/j.esmogo.2024.100046_bib14","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100046_bib15","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1053\/jhep.2003.50315","article-title":"The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club","volume":"38","author":"Moore","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100046_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmogo.2024.100046_bib17","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100046_bib18","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.21873\/anticanres.16452","article-title":"Evaluation of irinotecan and trifluridine\/tipiracil as fourth-line treatments after third-line nivolumab for advanced gastric cancer","volume":"43","author":"Hayashi","year":"2023","journal-title":"Anticancer Res"},{"issue":"6","key":"10.1016\/j.esmogo.2024.100046_bib19","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1007\/s10120-023-01427-9","article-title":"Efficacy and safety of trifluridine\/tipiracil plus ramucirumab in comparison with trifluridine\/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience","volume":"26","author":"Okunaka","year":"2023","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.esmogo.2024.100046_bib20","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221137135","article-title":"Real-world data of Trifluridine\/Tipiracil for patients with advanced gastric cancer: a multi-institutional retrospective study","volume":"16","author":"Matsumoto","year":"2022","journal-title":"Clin Med Insights Oncol"},{"issue":"11","key":"10.1016\/j.esmogo.2024.100046_bib21","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1007\/s00432-023-04813-z","article-title":"Effects of prior therapies on outcomes with trifluridine\/tipiracil in patients with metastatic gastric\/gastroesophageal junction cancer in a randomized phase III trial (TAGS)","volume":"149","author":"Shitara","year":"2023","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100046_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1007\/s10120-021-01271-9","article-title":"Efficacy and safety of trifluridine\/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)","volume":"25","author":"Shitara","year":"2022","journal-title":"Gastric Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2024.100046_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100234","article-title":"A\u00a0novel clinical prognostic index for patients with advanced gastric cancer: possible contribution to the continuum of care","volume":"6","author":"Shimozaki","year":"2021","journal-title":"ESMO Open"},{"issue":"18","key":"10.1016\/j.esmogo.2024.100046_bib24","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100046_bib25","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1186\/s12885-023-11199-1","article-title":"Randomised phase II trial of trifluridine\/tipiracil (FTD\/TPI) plus ramucirumab (RAM) versus trifluridine\/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)","volume":"23","author":"Takahashi","year":"2023","journal-title":"BMC Cancer"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:29:26Z","timestamp":1720236566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":25,"alternative-id":["S2949819824000074"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100046","relation":{},"ISSN":["2949-8198"],"issn-type":[{"type":"print","value":"2949-8198"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world outcomes of trifluridine\/tipiracil for heavily pretreated patients with advanced gastric cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100046"}}